Nilotinib, sold under the brand name Tasigna marketed worldwide by Novartis, is a medication used to treat chronic myelogenous leukemia (CML) which has...
20 KB (1,697 words) - 00:44, 27 August 2024
these changes resulted in the discovery of nilotinib. Nilotinib is a selective Bcr-Abl kinase inhibitor. Nilotinib is 10-30 fold more potent than imatinib...
56 KB (6,470 words) - 06:03, 24 October 2024
of imatinib. A second TK inhibitor, nilotinib, was approved by the FDA for the same indication. In 2010, nilotinib and dasatinib were also approved for...
34 KB (3,877 words) - 13:44, 25 October 2024
currently available inhibitors to treat CML are imatinib, dasatinib, nilotinib, bosutinib and ponatinib. Gastrointestinal stromal tumors (GIST) are known...
43 KB (5,251 words) - 10:44, 24 June 2024
journal). ALL and CML therapies have targeted JAK2 as well as BCR-ABL using nilotinib and ruxolitinib within murine models to downregulate downstream cytokine...
29 KB (3,538 words) - 15:01, 5 December 2023
This is a list of adverse effects of the anti-cancer drug nilotinib, sorted by frequency of occurrence. Very common (>10% incidence) adverse effects include:...
5 KB (463 words) - 16:57, 20 March 2022
sirolimus, alefacept, and the tyrosine kinase inhibitors, imatinib, nilotinib, and dasatinib. Experimental therapies under investigation include endothelin...
38 KB (3,293 words) - 18:29, 29 August 2024
Interferon-α Interleukin-2 Melphalan Methotrexate Mitoxantrone Nelarabine Nilotinib Oblimersen Pegaspargase Pentostatin Ponatinib Prednisone Rituximab Tretinoin...
1 KB (70 words) - 18:51, 14 November 2023
Approval of Dasatinib and Nilotinib for Resistant Leukemia MD Anderson researchers demonstrate the efficacy of dasatinib and nilotinib, leading to FDA approval...
54 KB (5,298 words) - 18:20, 16 October 2024
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
92 KB (8,729 words) - 03:44, 26 October 2024
Sorafenib (Nexavar) Sunitinib (Sutent) Dasatinib (Sprycel) Lapatinib (Tykerb) Nilotinib (Tasigna) Bosutinib (Bosulif) Ponatinib (Iclusig) Asciminib (Scemblix)...
20 KB (2,234 words) - 01:21, 22 July 2024
distinguishes dasatinib from other CML treatments, such as imatinib and nilotinib. Although dasatinib only has a plasma half-life of three to five hours...
22 KB (1,994 words) - 04:41, 3 January 2024
Stalevo (carbidopa/levodopa/entacapone) Parkinson's disease Tasigna (nilotinib) Chronic myelogenous leukemia (first-line treatment) 998 2012 39% NICE...
144 KB (12,146 words) - 04:28, 27 October 2024
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
68 KB (5,999 words) - 00:04, 25 October 2024
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
149 KB (15,703 words) - 20:22, 18 October 2024
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
42 KB (3,935 words) - 20:28, 27 October 2024
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
10 KB (600 words) - 04:23, 25 October 2024
ampicillin and amoxicillin; 2) anti-cancer medications, i.e., lorlatinib, nilotinib, imatinib (these three drugs are tyrosine kinase inhibitors that may also...
82 KB (8,872 words) - 00:26, 28 October 2024
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
24 KB (1,710 words) - 19:18, 30 August 2024
Mitomycin L01DC04 Ixabepilone L01EA01 Imatinib L01EA02 Dasatinib L01EA03 Nilotinib L01EA04 Bosutinib L01EA05 Ponatinib L01EA06 Asciminib L01EB01 Gefitinib...
12 KB (877 words) - 15:36, 25 January 2024
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
31 KB (3,428 words) - 18:05, 24 October 2024
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
121 KB (13,799 words) - 18:53, 22 October 2024
toxins and poisons. Various anti-cancer drugs like pazopanib, vandetanib, nilotinib, canertinib and erlotinib are known to be transported via OATPs (OATP-1B1...
13 KB (1,503 words) - 19:29, 31 December 2023
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
10 KB (1,131 words) - 19:14, 31 March 2024
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
64 KB (7,432 words) - 08:21, 28 October 2024
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
13 KB (1,177 words) - 02:19, 4 September 2024
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
18 KB (1,573 words) - 05:19, 15 October 2024
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
28 KB (2,570 words) - 16:18, 29 November 2023
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
24 KB (1,890 words) - 16:21, 4 October 2024
factor Kinase inhibitors: Agerafenib Axitinib Dasatinib Imatinib Masitinib Nilotinib Pazopanib Quizartinib Sorafenib Sunitinib Toceranib TGFβ See here instead...
26 KB (2,420 words) - 02:40, 26 September 2024